3//SEC Filing
ROGOFF FAMILY TRUST DTD 3
Accession 0001213900-21-031138
CIK 0001559356other
Filed
Jun 6, 8:00 PM ET
Accepted
Jun 7, 7:07 AM ET
Size
6.0 KB
Accession
0001213900-21-031138
Insider Transaction Report
Form 3
Holdings
Warrants (Right to Buy)
Exercise: $5.00From: 2019-02-13Exp: 2024-02-12→ Common Stock (20,000 underlying)- 8,266
Common Stock
Footnotes (1)
- [F1]According to the Annual Report on Form 10-K filed on April 15, 2021 (the "Form 10-K") by the issuer, Immune Therapeutics, Inc. (the "Company"), a reverse stock split of the Company's issued and outstanding, but not authorized, common stock at a ratio of 1,000-to-1 (the "Reverse Split") was approved by the Company's shareholders. The Reverse Split is currently pending approval by the Financial Industry Regulatory Authority, Inc. The information contained in the Form 10-K relating to the shares of Common Stock outstanding and beneficially owned is based on the implementation of the Reverse Split. The information presented herein is likewise based on the implementation of the Reverse Split. The beneficial ownership information presented in this Form 3 is otherwise based on the beneficial ownership of the Reporting Persons as of the date of the event requiring filing of this Form 3.
Documents
Issuer
Immune Therapeutics, Inc.
CIK 0001559356
Entity typeother
IncorporatedAZ
Related Parties
1- filerCIK 0001859552
Filing Metadata
- Form type
- 3
- Filed
- Jun 6, 8:00 PM ET
- Accepted
- Jun 7, 7:07 AM ET
- Size
- 6.0 KB